This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Advanced Cell Technology Announces 2012 Third Quarter Results

Advanced Cell Technology, Inc. (OTCBB: ACTC) (“ACT” or the “Company”), a leader in the field of regenerative medicine, announced today third quarter financial results for the period ended September 30, 2012.

Highlights from the third quarter included:
  • Treated first Dry Age-related Macular Degeneration (Dry AMD) and Stargardt’s Macular Dystrophy (SMD) patient with the higher dosage of hESC-Derived RPE cells in second cohort of the U.S. clinical trial at Wills Eye Institute in Philadelphia.
  • Closed out first patient cohorts in the U.S. and European Dry AMD and SMD clinical trials, which have four cohorts of three patients. The first cohort receives a dosage of 50,000 cells, the second receives 100,000 cells, the third receives 150,000 cells and the final cohort is to be dosed with 200,000 cells.
  • Secured approval to proceed with increased dosage into the second cohorts of SMD and AMD clinical trials.
  • Announced Scotland’s NHS Lothian as additional site for the Company’s European clinical trial using hESC-Derived RPE Cells to treat Macular Degeneration.
  • ACT was issued a broad patent covering human RPE cells derived from all types of pluripotent stem cells.
  • Secured a $35 million funding commitment from Lincoln Park Capital.

“We are excited with the developments we have seen in our U.S. and European trials and continue to accelerate enrollment in our clinical programs,” said Gary Rabin, Chairman and CEO of ACT. “We believe that these three trials could represent a paradigm shift in the way that stem cells are used in medicine and are pleased by the support we have received from our clinical trial site partners.”

2012 Third Quarter Financial Results

ACT had revenue totaling $68,184 for the three months ending September 30, 2012. The revenue relates to license fees and royalties collected. Research and Development expenses for the three months ended September 30, 2012 and 2011 were $2.8 and $4.0 million respectively. The lower R&D costs were primarily due to restricted stock issued to an R&D executive in 2011 which vested immediately as opposed to over a period of quarters in 2012.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.69 -1.20%
FB $117.51 0.67%
GOOG $693.97 0.43%
TSLA $240.87 -2.80%
YHOO $36.65 0.16%


Chart of I:DJI
DOW 17,778.54 -52.22 -0.29%
S&P 500 2,063.56 -12.25 -0.59%
NASDAQ 4,771.9090 -33.3820 -0.69%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs